Clinical Trial Update: Study to Evaluate the Effectiveness of ABC+3TC +EFV in Once-Daily Regimens Versus KLT in Twice-Daily Regimens in Naive HIV Patients [Phase 3]

View source ↗

Summary

A Phase 3 trial comparing once-daily ABC+3TC+EFV versus twice-daily KLT in treatment-naive HIV patients has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• ABC+3TC+EFV (abacavir/lamivudine/efavirenz)
• KLT

Snippet

Sponsor: Germans Trias i Pujol Hospital | Conditions: HIV Infections | Phase 3 | Status: COMPLETED